On June 15, NCPA will be represented at FDA’s annual listening session on compounding by NCPA staff Steve Postal and NCPA members — and meeting presenters — Steve Hoffart and Cheri Garvin. NCPA submitted its written statement for the record ahead of the listening session on compounding, covering concerns with GFI #256 (compounding animal drugs from bulk substances), patient access to compounded bioidentical hormone therapy, drug shortages, and adverse event reporting.